S1403, A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (CTMS #15-2060)
Objective: The purpose of this study is to compare the effects, good and/or bad, of using afatinib along with cetuximab to using afatinib alone in participants with non-small cell lung cancer which has an EGFR positive genetic mutation. The addition of cetuximab to the usual afatinib could shrink the cancer, but it could also cause side effects. The study will be considered positive if the study approach increases life by eight months or more compared to the usual approach.
To enroll or if you have questions about participation